Association of Arsenic Methylation Capacity with Developmental Delays and Health Status in Children: A Prospective Case-Control Trial

Yu Mei Hsueh, Wei Jen Chen, Chih Ying Lee, Ssu Ning Chien, Horng Sheng Shiue, Shiau Rung Huang, Ming I. Lin, Shu Chi Mu, Ru Lan Hsieh

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

This case-control study identified the association between the arsenic methylation capacity and developmental delays and explored the association of this capacity with the health status of children. We recruited 120 children with developmental delays and 120 age-and sex-matched children without developmental delays. The health status of the children was assessed using the Pediatric Quality of Life Inventory (PedsQL) and Pediatric Outcomes Data Collection Instrument (PODCI). The arsenic methylation capacity was determined by the percentages of inorganic arsenic (InAs%), monomethylarsonic acid (MMA V %), and dimethylarsinic acid (DMA V %) through liquid chromatography and hydride generation atomic absorption spectrometry. Developmental delays were significantly positively associated with the total urinary arsenic concentration, InAs%, and MMA V %, and was significantly negatively associated with DMA V % in a dose-dependent manner. MMA V % was negatively associated with the health-related quality of life (HRQOL-1.19 to-1.46, P < 0.01) and functional performance (-0.82 to-1.14, P < 0.01), whereas DMA V % was positively associated with HRQOL (0.33-0.35, P < 0.05) and functional performance (0.21-0.39, P < 0.01-0.05) in all children and in those with developmental delays. The arsenic methylation capacity is dose-dependently associated with developmental delays and with the health status of children, particularly those with developmental delays.

原文英語
文章編號37287
期刊Scientific Reports
6
DOIs
出版狀態已發佈 - 十一月 17 2016

指紋

Arsenic
Methylation
Health Status
Quality of Life
Cacodylic Acid
Pediatrics
Liquid Chromatography
Case-Control Studies
Spectrum Analysis
Equipment and Supplies

ASJC Scopus subject areas

  • General

引用此文

Association of Arsenic Methylation Capacity with Developmental Delays and Health Status in Children : A Prospective Case-Control Trial. / Hsueh, Yu Mei; Chen, Wei Jen; Lee, Chih Ying; Chien, Ssu Ning; Shiue, Horng Sheng; Huang, Shiau Rung; Lin, Ming I.; Mu, Shu Chi; Hsieh, Ru Lan.

於: Scientific Reports, 卷 6, 37287, 17.11.2016.

研究成果: 雜誌貢獻文章

Hsueh, Yu Mei ; Chen, Wei Jen ; Lee, Chih Ying ; Chien, Ssu Ning ; Shiue, Horng Sheng ; Huang, Shiau Rung ; Lin, Ming I. ; Mu, Shu Chi ; Hsieh, Ru Lan. / Association of Arsenic Methylation Capacity with Developmental Delays and Health Status in Children : A Prospective Case-Control Trial. 於: Scientific Reports. 2016 ; 卷 6.
@article{1b4b1bdb5fa94ce68031bb12139b5a59,
title = "Association of Arsenic Methylation Capacity with Developmental Delays and Health Status in Children: A Prospective Case-Control Trial",
abstract = "This case-control study identified the association between the arsenic methylation capacity and developmental delays and explored the association of this capacity with the health status of children. We recruited 120 children with developmental delays and 120 age-and sex-matched children without developmental delays. The health status of the children was assessed using the Pediatric Quality of Life Inventory (PedsQL) and Pediatric Outcomes Data Collection Instrument (PODCI). The arsenic methylation capacity was determined by the percentages of inorganic arsenic (InAs{\%}), monomethylarsonic acid (MMA V {\%}), and dimethylarsinic acid (DMA V {\%}) through liquid chromatography and hydride generation atomic absorption spectrometry. Developmental delays were significantly positively associated with the total urinary arsenic concentration, InAs{\%}, and MMA V {\%}, and was significantly negatively associated with DMA V {\%} in a dose-dependent manner. MMA V {\%} was negatively associated with the health-related quality of life (HRQOL-1.19 to-1.46, P < 0.01) and functional performance (-0.82 to-1.14, P < 0.01), whereas DMA V {\%} was positively associated with HRQOL (0.33-0.35, P < 0.05) and functional performance (0.21-0.39, P < 0.01-0.05) in all children and in those with developmental delays. The arsenic methylation capacity is dose-dependently associated with developmental delays and with the health status of children, particularly those with developmental delays.",
author = "Hsueh, {Yu Mei} and Chen, {Wei Jen} and Lee, {Chih Ying} and Chien, {Ssu Ning} and Shiue, {Horng Sheng} and Huang, {Shiau Rung} and Lin, {Ming I.} and Mu, {Shu Chi} and Hsieh, {Ru Lan}",
year = "2016",
month = "11",
day = "17",
doi = "10.1038/srep37287",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Association of Arsenic Methylation Capacity with Developmental Delays and Health Status in Children

T2 - A Prospective Case-Control Trial

AU - Hsueh, Yu Mei

AU - Chen, Wei Jen

AU - Lee, Chih Ying

AU - Chien, Ssu Ning

AU - Shiue, Horng Sheng

AU - Huang, Shiau Rung

AU - Lin, Ming I.

AU - Mu, Shu Chi

AU - Hsieh, Ru Lan

PY - 2016/11/17

Y1 - 2016/11/17

N2 - This case-control study identified the association between the arsenic methylation capacity and developmental delays and explored the association of this capacity with the health status of children. We recruited 120 children with developmental delays and 120 age-and sex-matched children without developmental delays. The health status of the children was assessed using the Pediatric Quality of Life Inventory (PedsQL) and Pediatric Outcomes Data Collection Instrument (PODCI). The arsenic methylation capacity was determined by the percentages of inorganic arsenic (InAs%), monomethylarsonic acid (MMA V %), and dimethylarsinic acid (DMA V %) through liquid chromatography and hydride generation atomic absorption spectrometry. Developmental delays were significantly positively associated with the total urinary arsenic concentration, InAs%, and MMA V %, and was significantly negatively associated with DMA V % in a dose-dependent manner. MMA V % was negatively associated with the health-related quality of life (HRQOL-1.19 to-1.46, P < 0.01) and functional performance (-0.82 to-1.14, P < 0.01), whereas DMA V % was positively associated with HRQOL (0.33-0.35, P < 0.05) and functional performance (0.21-0.39, P < 0.01-0.05) in all children and in those with developmental delays. The arsenic methylation capacity is dose-dependently associated with developmental delays and with the health status of children, particularly those with developmental delays.

AB - This case-control study identified the association between the arsenic methylation capacity and developmental delays and explored the association of this capacity with the health status of children. We recruited 120 children with developmental delays and 120 age-and sex-matched children without developmental delays. The health status of the children was assessed using the Pediatric Quality of Life Inventory (PedsQL) and Pediatric Outcomes Data Collection Instrument (PODCI). The arsenic methylation capacity was determined by the percentages of inorganic arsenic (InAs%), monomethylarsonic acid (MMA V %), and dimethylarsinic acid (DMA V %) through liquid chromatography and hydride generation atomic absorption spectrometry. Developmental delays were significantly positively associated with the total urinary arsenic concentration, InAs%, and MMA V %, and was significantly negatively associated with DMA V % in a dose-dependent manner. MMA V % was negatively associated with the health-related quality of life (HRQOL-1.19 to-1.46, P < 0.01) and functional performance (-0.82 to-1.14, P < 0.01), whereas DMA V % was positively associated with HRQOL (0.33-0.35, P < 0.05) and functional performance (0.21-0.39, P < 0.01-0.05) in all children and in those with developmental delays. The arsenic methylation capacity is dose-dependently associated with developmental delays and with the health status of children, particularly those with developmental delays.

UR - http://www.scopus.com/inward/record.url?scp=84995563231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995563231&partnerID=8YFLogxK

U2 - 10.1038/srep37287

DO - 10.1038/srep37287

M3 - Article

AN - SCOPUS:84995563231

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 37287

ER -